Collagen cross-linking is gaining popularity not only for arresting the progression of keratoconus but also other indications including management of corneal infections. In this review article, we analyzed the published literature to understand the level of evidence for its use in corneal ulcer. Photoactivated riboflavin and ultraviolet A light are known to possess antimicrobial properties. The treatment also induces formation of inter-and intra-fibrillar bonds, thereby making the corneal collagen resistant to the action of proteases arresting stromal melt. Both properties are well documented in in vitro experiments. The antimicrobial action is seen against bacteria, fungi, and parasites. The animal experiments have documented its efficacy against bacterial and fungal keratitis models. The literature on its application in human corneal infection is highly variable and comprises case reports, case series, and comparative nonrandomized and randomized trials. The treatment has been used as primary treatment, adjunctive treatment along with antibiotics, as the first line of treatment as well as for failed medical treatment cases. Even the cases included are of variable severity caused by a variety of microorganisms including culture-negative cases. Furthermore, the treatment protocols are also variable. While most reports show beneficial effects for bacterial corneal ulcer cases, especially those with superficial infiltrate, the effect has been mixed for fungal and parasitic keratitis. In view of these characteristics, we infer that the level of evidence for its use in corneal ulcer is at most weak. We need well-characterized, high-quality, clinical trials of sufficient power to assess its true value.
Introduction

C
orneal collagen cross-linking (CXL) is a procedure, wherein a photosensitizer (riboflavin) and ultraviolet (UV) light are used to strengthen cornea by promoting formation of inter-and intra-fibrillar covalent bonds. The currently employed CXL techniques were developed by researchers at the University of Dresden in the late 1990s. [1] The experiments showed that cross-linked porcine and rabbit corneas were stiffer and more resistant to enzymatic digestion. The corneas were also shown to contain higher molecular weight polymers of collagen due to fibril cross-linking. Safety studies showed that the procedure is safe if the corneal thickness exceeded 400 µ.
In 2003, human studies began in Dresden, and early results were promising. Since then, the procedure is gaining popularity among physicians across the globe. It was initially developed for halting progression of keratoconus. But over time, indications of its use kept on expanding and physicians started exploring the possibility of its use in corneal infections. However, while there is a general agreement on safety and efficacy of its use in ectatic disorders of the cornea and the treatment protocols standardized, the use for infectious keratitis has attracted a great amount of debate. Therefore, it will be prudent to review published literature and generate evidences in favor or against its use for corneal infection.
The aims of this review article are to:
• Understand the basis of its use in corneal infections
• Summarize in vitro and in vivo experimental studies and human experience • Analyze the data and understand its role as well as limitations in the management of corneal ulcer.
What is the Basis for the Use of Corneal Collagen Cross-linking in Corneal Infections?
The pathology of corneal infection comprises invasion by microorganisms accompanied by stromal infiltration by acute inflammatory cells both of which in turn result in release of cytokines including matrix metalloproteinases that degrade corneal collagen and lead to cell death and tissue necrosis.
The process results into breakdown and loss of collagen, progressive thinning of the cornea, and in extreme cases, perforation. Further, despite effective antimicrobial therapy, the tissue damage initiated by inflammatory cells and microorganisms continues long after the control of infection. Therefore, in addition to antimicrobial therapy, there has always been a search for safe anti-inflammatory as well as anti-collagenolytic therapy in the management protocols of corneal infections. The debate on the use of corticosteroid in corneal infections is continuing since 1950 though we made some success in understanding its uses after the landmark Steroid for Corneal Ulcer Trial. [2] Based on the existing evidences, we can safely infer that a protocol that provides antimicrobial properties or synergizes actions of currently used antimicrobial agents and simultaneously makes corneal collagen resistant to the action of collagenolytic enzymes will be desirable. Collagen cross-linking protocols currently in use potentially provide both these properties.
Antimicrobial properties
In the 1960s, Tsugita et al. reported that the application of riboflavin and UVA light leads to inactivation of tobacco mosaic virus. [3] Since then, this knowledge has been used to eradicate microorganisms such as in sterilization of water, surfaces, food, and blood product. The release of reactive oxygen species on activation of riboflavin by UVA light results in damage to DNA and RNA of pathogens. In addition, UV irradiation on its own damages nucleic acid and has virucidal, bactericidal, and fungicidal effects.
Martins et al. studied antimicrobial properties of riboflavin and UVA light against a variety of keratitis pathogens including antibiotic sensitive and resistant organisms. [4] The authors found that the growth inhibition zone (GIZ) was significantly greater with combined riboflavin and UVA exposure compared to UVA alone. However, the inhibition effect was not noticed for Candida albicans. The authors concluded that CXL using riboflavin and UVA light can be new potential treatment for infectious keratitis. [5] [6] [7] [8] [9] Richoz et al. conducted a study to analyze whether optimized photoactivated chromophore treatment maintains antibacterial efficacy. [8] The results of the study showed that the antibacterial efficacy follows the Bunsen-Roscoe law of reciprocity and can be maintained even when the irradiation intensity is considerably increased.
In yet another experiment, Bäckman et al. found that longer UVA exposure time in combination with lower riboflavin levels was more efficient in killing bacteria compared to the standard cross-linking settings. [10] Riboflavin/UVA treatment has been found to be effective against fungal pathogens as well. Experiments conducted by Sauer et al. on the following three groups of fungi: C. albicans, Fusarium sp., and Aspergillus fumigatus showed that these strains did not show any increased GIZ without previous amphotericin-B medication. However, GIZ was significantly greater after pretreatment with amphotericin-B and exposure to riboflavin/UVA. The authors concluded that CXL enhances the effect of amphotericin-B on fungal cell membranes. [11] Qualitative and quantitative measurements of C. albicans and Fusarium solani strains after exposure to CXL treatment showed a significant decrease in numbers and alterations of cell morphology. [12] Del Buey et al. evaluated antiamoebic activity of CXL and found that single application of the treatment does not eradicate Acanthamoeba. [13] Makdoumi et al. also found that the growth inhibition was primarily due to antiprotozoal effect of UVA light, and riboflavin does not amplify it further. [14] Strengthening corneal collagen against degradation by collagenolytic enzymes Cornea is made up of collagen fibrils enmeshed in the matrix of proteoglycans, proteins, and glycoproteins. The cellular component primarily comprising keratocytes resides between collagen lamellae. Collagen cross-linking results into the formation of chemical bonds between adjacent fibrils, thereby providing mechanical strength. In addition, the cornea becomes relatively resistant to enzymatic digestion by a variety of collagenases. This same mechanism is the basis of its use in the management of keratoconus.
The work of Wollensak et al. evaluating biomechanical effect of cross-linked porcine and human corneas using a microcomputer-controlled biomaterial tester showed that the procedure results in increase in mechanical rigidity in porcine and human corneas. [15] The increase was greater in human corneas. In another study, the same group postulated that the increased biomechanical rigidity is secondary to increase in diameter of corneal collagen. [16] He et al. who used quantitative noninvasive ultrasound method reproduced similar findings. [17] Spoerl et al. used ocular response analyzer software and found that keratoconic corneas show altered biomechanical properties after cross-linking. [18] Spoerl et al. also showed that porcine corneas after CXL showed a marked increase in resistance to enzymatic digestion when exposed to pepsin, trypsin, and collagenase solutions compared to controls. [19] In addition to these properties, studies have also found riboflavin to have anti-inflammatory and nociceptive effects. [20] The later was corroborated by Shetty et al. who reported a significant decrease in pain following CXL in patients of refractory advanced microbial keratitis. [21] Overall, the laboratory data suggest that CXL of the cornea using riboflavin and UVA light not only has potential for eliminating offending pathogens but also confers corneal rigidity that reduces its susceptibility to proteolytic enzymes and corneal melt. In addition, it has anti-inflammatory effect. All of these effects justify its use in the management of corneal ulcer.
Are these Results Translated in In vivo
Animal Experiments?
Review of literature in English language using PubMed showed that few studies have been carried out to evaluate the efficacy of CXL in animal corneal infection models.
Tal et al. evaluated the efficacy of corneal CXL as primary therapy for S. aureus corneal ulcer in rabbit model. [22] Forty rabbits were randomly assigned to four groups: group-A: No treatment (control); Group-B: Topical antibiotic treatment (cefazolin 50 mg/mL, Garamycin 14 mg/mL drops, and chloramphenicol 5% ointment every 2 h); Group-C: CXL; and Group-D: CXL + topical antibiotics. After 1 month of treatment, Group-C ulcers had the smallest mean scar diameter and shortest mean healing time.
Cosar et al. studied the effects of CXL on the penetration of topical 0.5% moxifloxacin, number of colony-forming units (CFUs), and the clinical course of infection in Pseudomonas aeruginosa rabbit keratitis model. [23] Although there was a significant difference in the clinical improvement between moxifloxacin group and moxifloxacin with CXL group, there was no difference in CFU counts between two groups. Authors concluded that the synergistic effect of CXL as reflected by clinical cure in the treatment of corneal ulcer is not just through enhanced antibiotic penetrance or efficacy.
CXL treatment has also been studied in rabbit models of Fusarium. [24] After the infection was established, the rabbits were divided into two groups -one group did not receive any treatment (control) while another group underwent CXL. The CXL group showed superior clinical improvement and has significantly less fungal load as demonstrated by the number of CFUs compared to controls. In addition, evaluation of excised corneas showed that CXL-treated corneas had fewer Fusarium hyphae and inflammatory cells.
CXL treatment, however, was not found effective in rabbit model of Acanthamoeba keratitis. [25] 
What is the Evidence of Its Use in Human
Corneal Infection?
The use of CXL for keratoconus established the safety and efficacy of the procedure in strengthening corneal collagen. This along with the theoretical basis mentioned above prompted clinicians to use CXL for microbial keratitis cases as well. This resulted in a variety of publications ranging from case reports to large and small case series and even prospective randomized or nonrandomized clinical trials. The authors used CXL as sole primary treatment, adjuvant to specific medical treatment, and as supplemental treatment in failed medical treatment cases. The procedure has been tried against a variety of pathogens including drug sensitive and resistant bacteria, fungi, and parasites. Few authors have even attempted systematic review or meta-analysis of the published literature. A wide variety in the publications clearly points that the application of CXL for this indication is still evolving and our understanding of its level of effectiveness still not mature.
Since Theo Seiler group took lead and carried out laboratory experiments to understand fundamental basis of the use of CXL for corneal infection, they were the first to publish its use in human corneal infection. [26] They reported CXL treatment in five patients of infectious keratitis that did not respond to systemic and topical antibiotic therapy and documented that the progression of corneal melting was halted and the infiltrate size reduced in four of five patients after CXL treatment. The authors concluded that the procedure may be used in therapy-resistant cases to avoid emergency keratoplasty.
Similar results on using CXL as adjunctive treatment in medically resistant cases have been published by other authors. [27] [28] [29] [30] [31] Shetty et al. have used CXL treatment in 15 eyes of microbial keratitis caused by bacteria and fungi. [21] The patients received treatment with antibiotics/antifungals for 2 weeks before CXL treatment. Six of nine patients with bacterial keratitis and three of six patients with fungal keratitis resolved following CXL treatment. Patients with deep stromal keratitis or endothelial plaque failed to resolve. All patients had resolution of pain on the 1 st postoperative day. There was an appearance of or increase in hypopyon in seven patients. The authors concluded that CXL can be used as adjunctive therapy in nonresolving microbial keratitis with superficial stromal involvement.
Panda et al. published its use in seven refractory corneal ulcers managed medically for 4-12 weeks. [29] In all cases, the progression of corneal melting was halted after CXL treatment. Skaat et al. reported six patients with severe refractory infectious keratitis treated with CXL. [30] In five cases, signs of infection and inflammation resolved within 1-2 weeks after the treatment. However, one patient required penetrating keratoplasty. Sorkhabi et al. used CXL therapy for resistant corneal ulcers and concluded that CXL is a viable therapeutic option for the treatment of corneal ulcers and can be used as an adjuvant in resistant cases. [31] Can Corneal Collagen Cross-linking Be Used in Combination with Antibiotics as Primary Treatment?
Price et al. published a prospective case series of forty patients with microbial keratitis treated by CXL while continuing on standard antimicrobial treatment. [32] The primary outcome measures were the time to resolution of the infiltrate and the epithelial defect. In six patients, the keratitis did not resolve, and the eyes required penetrating keratoplasty. The authors concluded that the CXL is most effective in superficial infections and bacterial etiology. The authors also cautioned that it should be avoided in viral infections.
Can it Be Used as Sole Treatment without Antibiotics?
Makdoumi et al. have described the use of CXL as a primary therapy for bacterial keratitis. [33] In a prospective nonrandomized study, they included 16 patients of microbial keratitis without primary treatment. All eyes responded to the photochemical treatment with improvement in symptoms and signs. Epithelial healing was achieved in all cases. Antibiotic administration was necessary in two cases only. In addition, one patient required amniotic membrane transplant. One thing to note, however, is that the size of infiltrate in this series was much smaller.
What is the Experience with Fungal and Parasitic Infections?
In addition to the cases included in case series mentioned in the previous sections, Li et al. reported successful use of CXL for eight cases of microbiologically proven fungal keratitis. [34] CXL treatment was performed between 5 days and 1 month from the time of initial presentation. The healing of corneal epithelium and ulcer was achieved in all cases 3-8 days after CXL treatment. None of the cases required corneal transplantation.
On the contrary, Uddaraju et al. in a prospective randomized clinical trial found that CXL is not helpful in deep stromal fungal keratitis. [35] Five eyes in the CXL group and three eyes in the non-CXL group experienced treatment failure by 6 weeks (P = 0.56). In a secondary analysis, the CXL group experienced more perforations than the non-CXL group (4 vs. 0, respectively; P = 0.02). Vajpayee et al. in a retrospective analysis also found no difference in average healing time and final visual acuity between groups with medical management alone and medical management with CXL. [36] The authors concluded that CXL as an additional treatment has no advantage over medical treatment alone for moderate fungal keratitis cases.
Experience with CXL for Acanthamoeba keratitis is very limited. In a recently published meta-analysis, Papaioannou et al. found that 10 of 11 eyes were successfully managed using CXL as adjunctive treatment. [37] Most of these cases were reported as a case report or small series, and therefore, the evidence is insufficient to draw valid conclusions. [38, 39] Is There Any Randomized Comparative Clinical Trial Assessing the Efficacy of the Procedure?
As of 2015, two prospective comparative clinical trials assessing the efficacy of CXL compared to conventional treatment have been published. Said et al. included forty patients with advanced infectious keratitis coexisting with corneal melting due to bacteria, fungi, Acanthamoeba, and mixed organism. [28] Twenty-one patients underwent CXL treatment in addition to antimicrobial therapy. The control group consisted of 19 patients who received antimicrobial therapy only. CXL with photoactivated riboflavin did not shorten the time to corneal healing. However, the complication rate of perforation was more in the control group while none of the cases in CXL group developed the complication. The authors concluded that CXL is an effective adjuvant therapy in the management of severe infectious keratitis associated with corneal melting and prevents corneal perforation.
In another randomized comparative clinical trial, Bamdad et al. randomized 32 moderately severe corneal ulcer cases into those who received CXL in addition to medical treatment and controls who were treated using standard medical treatment alone. [40] The mean treatment After going through the preceding section, one will be inclined to infer that there is sufficient evidence in favor of the use of CXL for microbial keratitis. It not only prevents stromal melt and corneal perforation but also promotes resolution of ulcer including those cases that otherwise fail to respond to medical treatment.
However, we need to exercise caution in making these conclusions. The reasons are:
• The evidence is weak. As of 2016, only two prospective comparative studies evaluating efficacy of CXL in human corneal ulcer have been published. Of these, only one used randomization. The sample size was inadequate in both of these. Therefore, most of the evidence is in the form of case reports and case series that is considered weak evidence • The reports describe cases with variable disease severity from very small superficial infiltrate to moderately severe keratitis with stromal melt. No standard or well-defined definitions of severity were used in these reports • The authors have included keratitis cases caused by a wide variety of organisms including bacteria, fungi, parasites, herpes simplex virus, and culture-negative cases. While the number of bacterial keratitis cases is high enough, the literature provides only limited experience for infection by other organisms • Authors in these studies have used variable protocol of CXL treatment. While majority have used conventional protocol with irradiation of 365 nm and 3 mW/cm, 2 duration of exposure was variable. There is a report of using accelerated protocol (365 nm and 9 mW/cm 2 for 10 min) in a case of fungal keratitis • The definition of treatment failure for subjecting a case to CXL treatment was not uniform. This is obvious from the fact that the duration of treatment before enrollment in the CXL studies ranged between 1 and 168 days in bacterial ulcer, 1 and 84 days for fungal, and 1 day and 1 year for Acanthamoeba keratitis cases • The term "stromal melt" is vague, and the data on residual stromal thickness or extent of melt are not provided. Therefore, one cannot make conclusions on its safe use in the presence of severe stromal loss and thinning. The experience in keratoconus suggests that the procedure is safe only if the corneal thickness is at least 400 µ. Does that apply to microbial keratitis as well cannot be answered based on the published literature. Further, the stromal loss in corneal infection is not uniform, and the possibility of finding areas of significant stromal loss and normal thickness within the same cornea cannot be ruled out • The benefits of CXL treatment for fungal and Acanthamoeba are not uniform. Laboratory, animal, and human experience is mixed and does not provide a clear evidence in favor or against its use for these cases.
Conclusions
The collagen cross-linking seems promising and can provide an alternative adjunctive treatment option in the management of corneal ulcer, especially those caused by bacteria and associated with superficial infiltrate. The use of CXL in fungal and Acanthamoeba keratitis seems to be controversial and best avoided. We need more research, especially using appropriately powered randomized controlled trials to assess its true value. It will also be important to use well-characterized protocols including case definition, inclusion and exclusion criteria, and outcome measures. Further, it will also be important to publish both positive and negative results.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
